Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, randomized, open–label study to evaluate the efficacy and tolerability of treatment with vafidemstat in combination with standard of care treatment to prevent Acute Respiratory Distress Syndrome (ARDS) in adult severely ill patients with COVID-19

Next Previous
Trial Profile

A Phase II, randomized, open–label study to evaluate the efficacy and tolerability of treatment with vafidemstat in combination with standard of care treatment to prevent Acute Respiratory Distress Syndrome (ARDS) in adult severely ill patients with COVID-19

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vafidemstat (Primary)
  • Indications Respiratory insufficiency; SARS-CoV-2 acute respiratory disease
  • Focus Therapeutic Use
  • Acronyms ESCAPE
  • Sponsors Oryzon

Most Recent Events

  • 07 Jul 2023 Status changed from active, no longer recruiting to completed.
  • 29 Jul 2021 Status changed from recruiting to active, no longer recruiting, according to an Oryzon media release.
  • 09 Jul 2021 According to an Oryzon media release, preliminary results from this trial were presented at the 31st European Congress of Clinical Microbiology and Infectious Diseases, ECCMID-2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top